KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Jeff P Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Maria Thadani-Mulero, Oscar Cazares, Weize Huang, Yanwen Jiang, Emma Clark, Hyun Yong Jin, Michelle Boyer, Franck Morschhauser

Blood 147(24) 2895-2904

PMID41770817
PMCIDPMC13277654
DOI10.1182/blood.2025030630
发表日期2026-03-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The phase 3 CRISTALLO trial compared first-line fixed-duration venetoclax-obinutuzumab (VenO) vs fludarabine, cyclophosphamide, and rituximab (FCR)/bendamustine-rituximab (BR) in patients with chronic lymphocytic leukemia (CLL), using undetectable minimal residual disease (uMRD) as the sole primary end point. Previously untreated patients with a cumulative illness rating scale score ≤6 and creatinine clearance ≥70 mL/min without del(17p)/TP53 mutations were randomized 1:1 to VenO or FCR/BR. The primary end point was uMRD (<10-4) in peripheral blood (PB) using next-generation sequencing at month 15. Key secondary end points included uMRD (<10-4) in PB and bone marrow (BM) at end of treatment (EOT) and progression-free survival (PFS). uMRD at deeper cutoffs were explored. At data cutoff (19 March 2024), 80 patients received VenO, and 86 received FCR/BR. Baseline characteristics were generally balanced across arms. The primary end point was met: 81.3% (VenO) and 54.7% (FCR/BR) achieved uMRD (<10-4) in PB at month 15 (P = .0004). uMRD (<10-4) in PB and BM at EOT was also higher with VenO vs FCR/BR. Short follow-up precluded evaluation of PFS at the first planned interim analysis; however, fewer patients progressed/died with VenO vs FCR/BR (7 vs 13). At month 15, 65.0% (VenO) and 25.6% (FCR/BR) achieved uMRD (<10-6) in PB. The overall safety profile was consistent with the known safety profile of each drug. No patient in the VenO arm was deemed high risk for tumor lysis syndrome (TLS) after obinutuzumab debulking; no clinical TLS occurred. These results confirm and extend the findings from the GAIA-CLL13 trial, validating increased depth of response with VenO vs chemoimmunotherapies. This trial was registered at www.clinicaltrials.gov as NCT04285567.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. Kaplan-Meier estimates of investigator-assessed PFS at the interim PFS analysis (ITT population). NE, not estimable.

Kaplan-Meier_estimates_of_investigator-assessed_PFS

PFS

Figure 3 · Panel Kaplan-Meier_estimates_of_investigator-assessed_PFS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_estimates_of_investigator-assessed_PFS 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Patient disposition (CONSORT diagram). ∗In the FCR/BR arm, 46 and 38 patients received FCR and BR treatment, respectively. One patient received rituximab only.
非 KM Figure
Figure 2Figure 2. Sankey plot of uMRD kinetics at various cutoffs in PB (ITT population). uMRD kinetics in the VenO (A) and FCR/BR (B) arms. ∗Includes missing samples, patients who discontinued treatment, experienced progressive disease (PD), or died. C, cycle; D, day.
非 KM Figure
Figure 4Figure 4. Sankey plot of TLS risk at baseline and at reassessment after 3 doses of obinutuzumab in the VenO arm (ITT population). TLS risk reassessment was conducted at cycle 1 day 22 (or cycle 1 days 16-21).
非 KM Figure
Figure 5Figure 5. Durability of uMRD over time (ITT population). The horizontal line indicates the cutoff at <1 CLL cell per 10 000 leukocytes as measured by NGS in PB. ∗End of combination treatment response visit (EOTRV) was performed 8 to 12 weeks after the last dose of combination therapy for the VenO arm or after the last dose of treatment for the FCR/BR arm; † Month 15 visit was performed 15 months after cycle 1 day 1 in all patients who did not have PD. FU, follow-up.
非 KM Figure
Figure 6Figure 6. MRD level at EOT estimated using dynamic MRD modeling. Each dot represents the individual best model estimated MRD at EOT. The thick solid black lines represent the median MRD level. The hinges (top and bottom of the boxes) represent the 25th and 75th percentiles (ie, interquartile range). The top and bottom whiskers extend to the largest and smallest values, respectively.
非 KM Figure